Compare Plby Group Inc (PLBY) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Plby Group Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Plby Group Inc trades at $0.97 (market cap $118.61M), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 42.3× Plby Group Inc's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Plby Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Plby Group Inc for 24 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| PLBY | TVTX | |
|---|---|---|
Market Cap | $118.61M | $5.02B |
Volume | 1,149,362 | 2,060,842 |
Sector | Consumer Cyclical | Health |
52-Week High | $2.71 | $67.52 |
52-Week Low | $0.98 | $26.79 |
Typical Hold Time | 24 Days | 0 Days |
Enterprise Value | $264.19M | $5.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PLBY Group trades at $1.02, up 2.7% today, amid a bearish technical outlook with mixed fundamentals. The company shows improving financial trends with revenue stabilizing around $120M and narrowing losses, but remains unprofitable with negative shareholder equity. Recent leadership appointments signal strategic focus on brand growth and licensing expansion.
While analyst consensus is strongly bullish (75% buy ratings), significant risks persist including high debt levels, negative equity, and inconsistent earnings performance. The stock's valuation appears stretched with a P/E of 51, requiring sustained operational improvement to justify current levels.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
